

FINAL EXAM
JUNE 2018

NATIONAL BOARD OF EXAMINATIONS

GASTROENTEROLOGY

PAPER-III

GASTRO/J/18/10/III

Time: 3 hours

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the question to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- | | | |
|-----|---|-----|
| 1. | a) Indications and brief technique of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) | 5+5 |
| | b) Role of radiofrequency ablation therapy in Gastroenterology | |
| 2. | a) Emerging anti-reflux endoscopic techniques | 5+5 |
| | b) Evaluation and management of colonic stricture in ulcerative colitis | |
| 3. | a) Classify various Gastrointestinal polyposis syndrome | 4+6 |
| | b) Molecular (genetic) alterations in the development of colon cancer. | |
| 4. | a) Clinically relevant classification of Crohn's disease and its implications for management | 5+5 |
| | b) Would you recommend surveillance for colon cancer in patients with inflammatory bowel disease? Give reasons. | |
| 5. | a) What are the immune mechanisms causing intestinal injury in celiac disease? | 6+4 |
| | b) Write a short note on Hirschsprung's disease | |
| 6. | a) Definition and causes of short bowel syndrome. | 4+6 |
| | b) Management of short bowel syndrome | |
| 7. | a) NSAID induced enteropathy: Pathophysiology, clinical features & management. | 5+5 |
| | b) How would you investigate and manage a 65-year-old patient presenting with acute abdominal pain and is found to have mesenteric venous thrombosis? | |
| 8. | a) Clinical features, investigations and management of small intestinal bacterial overgrowth | 5+5 |
| | b) Gut virome | |
| 9. | a) Fecal calprotectin | 5+5 |
| | b) Management of perianal fistula and abscess in patients who do not have inflammatory bowel disease | |
| 10. | a) Adalimumab: structure, pharmacology, indications in GI diseases and results | 5+5 |
| | b) Wnt/ β -catenin pathway in hepatocellular cancer | |
